LEUKEMIA: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance treatment for myeloma up to 70 years old

Intensive pre-treatment of newly diagnosed multiple myeloma (MM), including induction therapy (IT), high-dose melphalan (MEL200) and autologous hematopoietic stem cell transplantation (ASCT), followed by consolidation and/or maintenance therapy, mainly limited to The patient was 65 years old

Intensive pre-treatment of newly diagnosed multiple myeloma (MM), including induction therapy (IT), high-dose melphalan (MEL200) and autologous hematopoietic stem cell transplantation (ASCT), followed by consolidation and/or maintenance therapy, mainly limited to The patient was 65 years old

German Myeloma Multicenter Group (GMMG)-MM5 is a prospective, multicenter Phase III trial using bortezomib-based IT, pre-MEL200/ASCT and lenalidomide consolidation and maintenance for patients 18 to 70 years old Treatment, an analysis was performed, focusing on progression-free survival (PFS), overall survival (OS), time to progression (TTP), non-relapse mortality (NRM), response rate, and patient age-related toxicity

The IT in the GMMG-MM5 trial included three cycles of bortezomib/doxorubicin/dexamethasone (PAd, study group A1 + B1) or bortezomib/cyclophosphamide/dexamethasone (VCD, study group) A2 + B2), then stem cell mobilization/collection

Subsequently, two different lenalidomide maintenance treatment strategies were applied: lenalidomide for 2 years (LEN-2Y, study group A1 + A2) or only for patients who did not achieve complete remission (CR) at the beginning or before Lenalidomide during maintenance treatment for 2 years (LEN-CR, study group B1 + B2)

 

a, b Progression-free survival and overall survival (PFS, OS) of three randomly grouped age groups: ≤60 years (S1), 61-65 years (S2) and 66-70 years (S3), including single The variable Cox compares models for a single age group

a, b Progression-free survival and overall survival (PFS, OS) of three randomly grouped age groups: ≤60 years (S1), 61-65 years (S2) and 66-70 years (S3), including single The variable Cox compares models for a single age group

Compared with S1, the overall toxicity of S2 and S3 increased in all treatment stages (any adverse event/any serious adverse event: S1: 81.

Randomly grouped progression-free survival and overall survival subgroup analysis forest plot

Randomly grouped progression-free survival and overall survival subgroup analysis forest plot Randomly grouped progression-free survival and overall survival subgroup analysis forest plot

In summary, the current analysis shows that if it is considered suitable for transplantation, intensive treatment methods including IT, MEL200/ASCT, consolidation and maintenance treatment can be applied to patients under 70 years of age

In summary, the current analysis shows that if it is considered suitable for transplantation, intensive treatment methods including IT, MEL200/ASCT, consolidation and maintenance treatment can be applied to patients under 70 years of age

Original source:

Original source:

Mai EK,Miah K,Bertsch U,et al.

Mai EK,Miah K,Bertsch U,et al.
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
[J].
Leukemia,1970,:.


Leave a message here